Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • HOME
  • ABOUT US
  • POLICY HUB
  • OUR VALUES
  • OUR SERVICES
  • PRIVACY POLICY
  • CONTACT US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Drug PIC

Allergan Aesthetics’ JUVÉDERM VOLBELLA Wins NMPA Approval for Infraorbital Hollowing – Hyaluronic Acid Filler Expands China Label Beyond Lips

Fineline Cube Sep 11, 2026
Company Drug PIC

GSK’s Shingrix Wins Japan Approval for Prefilled Syringe Presentation – Recombinant Zoster Vaccine Gains Administration Flexibility

Fineline Cube Sep 11, 2026
Company Drug PIC

Hengrui’s Hetrombopag Wins China Approval for CTIT and Pediatric ITP – Oral TPO‑RA Expands Across Thrombocytopenia Indications

Fineline Cube Sep 11, 2026
Company Drug PIC

Roche’s Enspryng Granted FDA Priority Review for MOGAD – First IL‑6 Inhibitor Poised to Expand Beyond NMOSD

Fineline Cube Sep 11, 2026
Company Deals PIC

Boji Medical and Zhejiang Maiyata Sign Strategic Partnership – Leading China CRO Joins Microbiome Innovator to Advance Live Biotherapeutic Products

Fineline Cube Sep 11, 2026
Company Drug PIC

Allergan Aesthetics’ JUVÉDERM VOLBELLA Wins NMPA Approval for Infraorbital Hollowing – Hyaluronic Acid Filler Expands China Label Beyond Lips

Fineline Cube Sep 11, 2026
Policy / Regulatory

Hainan Boao Lecheng Pilot Zone Issues Exit Mechanism Rules for Clinical Translation of New Biomedical Technologies – Full‑Process Framework for Suspension, Exit and Resumption

Fineline Cube Sep 11, 2026
Company Drug

BRL Medicine’s Allogeneic CD19 CAR‑T Included in CDE’s “Care Program‑Extension” – Rare Disease Fast Track for Relapsed/Refractory Systemic Sclerosis

Fineline Cube Sep 11, 2026
Company Drug

Livzon’s YJH-012 siRNA Drug Gets NMPA Green Light for Gout Trials

Fineline Cube Jun 25, 2025

China-based Livzon Pharmaceutical Group Inc., (HKG: 1513) announced that its Category 1 chemical drug YJH-012...

Company Medical Device

GE Healthcare Wins FDA Approval for Vizamyl Label Update in Alzheimer’s Detection

Fineline Cube Jun 25, 2025

US medical device and life sciences giant GE Healthcare Technologies Inc., (NASDAQ: GEHC) announced that...

Policy / Regulatory

NHSA Emphasizes Management of Designated Medical Institutions for Healthcare Quality

Fineline Cube Jun 25, 2025

The National Healthcare Security Administration (NHSA) this week released a notification emphasizing the importance of...

Company Deals

Suzhou Porton Biologics Partners with Future Biotechnology to Expand Viral Vector Services

Fineline Cube Jun 25, 2025

China-based Contract Development and Manufacturing Organization (CDMO) Suzhou Porton Biologics Ltd announced this week a...

Company Drug

Lundbeck’s Lu AG13909 Wins Orphan Drug Designations for Congenital Adrenal Hyperplasia

Fineline Cube Jun 25, 2025

Denmark-based pharmaceutical company Lundbeck A/S (OTCMKTS: HLUBF) announced that it has received Orphan Drug Designations...

Company Drug

Henlius Biotech Doses First Patient in Japanese Bridging Trial of Serplulimab for ES-SCLC

Fineline Cube Jun 25, 2025

China-based Shanghai Henlius Biotech Inc. (HKG: 2696) announced the successful completion of first patient dosing...

Company Drug

C.Q. Pharma’s Prasugrel Clinical Filing Accepted by China’s NMPA

Fineline Cube Jun 25, 2025

China-based C.Q. Pharmaceutical Holding Co., Ltd (SHE: 000950) announced that its clinical application for prasugrel...

Company Drug

BeOne Medicines Launches Ziihera for HER2-High Biliary Tract Cancer in China

Fineline Cube Jun 25, 2025

China-based BeOne Medicines Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235) announced the official commercial availability...

Company Deals

TINGSN Technology Secures RMB 100M in Series B+ Round for 4D Intracardiac Ultrasound R&D

Fineline Cube Jun 25, 2025

China-based TINGSN Technology has reportedly secured RMB 100 million (USD 14 million) in a Series...

Company Deals

Bayer and Tsinghua University Renew Strategic Research Pact for Drug Innovation

Fineline Cube Jun 25, 2025

German pharmaceutical giant Bayer AG (ETR: BAYN) and Tsinghua University announced the signing of their...

Company Medical Device

Dynamiker Bio’s Aspergillus Detection Kit Wins NMPA Marketing Approval

Fineline Cube Jun 25, 2025

China-based Dynamiker Biotechnology (Tianjin) Co., Ltd. announced that it has received marketing approval from the...

Company Drug

GSK Gains FDA Clearance for Benlysta Autoinjector in Pediatric Lupus Nephritis

Fineline Cube Jun 25, 2025

UK-based GlaxoSmithKline (GSK; NYSE: GSK) announced that it has received clearance from the US Food...

Company Drug

Medilink Therapeutics’ YL201 Wins FDA Breakthrough Therapy Designation for SCLC

Fineline Cube Jun 25, 2025

Suzhou-based Medilink Therapeutics announced that it has received Breakthrough Therapy Designation (BTD) from the US...

Company Deals Hospital Medical Device

Siemens Healthineers Collaborates with MGH to Advance Theranostics Applications

Fineline Cube Jun 25, 2025

Siemens Healthineers AG (ETR: SHL), a Germany-based medical device giant, has entered into a research...

Company Drug

FDA Approves AstraZeneca’s Datopotamab deruxtecan for EGFR-Mutated NSCLC

Fineline Cube Jun 25, 2025

The US Food and Drug Administration (FDA) this week approved Datopotamab deruxtecan (Dato-DXd), a TROP-2-targeted...

Company Drug

TransThera Sciences’ Tinengotinib Gains FDA Fast Track for mCRPC Treatment

Fineline Cube Jun 25, 2025

China-headquartered TransThera Sciences (Nanjing) Inc., (HKG: 2617), which listed in Hong Kong this week, announced...

Company Deals Drug

XtalPi Signs LOI With DoveTree for AI-Powered Drug Development

Fineline Cube Jun 25, 2025

Shenzhen-based QuantumPharm Inc., known as Xtalpi Inc. (HKG: 2228), announced the signing of a Letter...

Company Drug

Merck’s Prevymis Approved in China for Pediatric CMV Prevention

Fineline Cube Jun 25, 2025

US-based pharmaceutical giant Merck, Sharp & Dohme (MSD, NYSE: MRK) announced that its novel non-nucleoside...

Company Drug

Sansure Biotech Wins NMPA Approval for Fungal Infection Detection Kit

Fineline Cube Jun 24, 2025

China’s National Medical Products Administration (NMPA) has approved Sansure Biotech Inc.’s (SHA: 688289) Pneumocystis jirovecii,...

Company Medical Device

Broncus Medical Wins NMPA Approval for BroncAblate RFA System Console

Fineline Cube Jun 24, 2025

Shanghai and Hangzhou (China), and San Jose and Seattle (United States)-based Broncus Medical (HKG: 2216)...

Posts pagination

1 … 191 192 193 … 719

Recent updates

  • Hainan Boao Lecheng Pilot Zone Issues Exit Mechanism Rules for Clinical Translation of New Biomedical Technologies – Full‑Process Framework for Suspension, Exit and Resumption
  • BRL Medicine’s Allogeneic CD19 CAR‑T Included in CDE’s “Care Program‑Extension” – Rare Disease Fast Track for Relapsed/Refractory Systemic Sclerosis
  • Walvax’s Third‑Generation COVID‑19 mRNA Vaccine Wins NMPA Approval – JN.1‑Based Shot Clears Regulatory Bar for Adults in China
  • China’s Seventh National VBP Round for Medical Consumables Concludes in Tianjin – 517 Digestive Intervention Products Selected Across 23 Categories
  • Ocumension’s OT‑301 NDA Accepted by China’s CDE – Dual‑Mechanism Glaucoma Therapy Advances Toward Approval in Open‑Angle Glaucoma and Ocular Hypertension
business cooperation with fineline tech

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Policy / Regulatory

Hainan Boao Lecheng Pilot Zone Issues Exit Mechanism Rules for Clinical Translation of New Biomedical Technologies – Full‑Process Framework for Suspension, Exit and Resumption

Company Drug

BRL Medicine’s Allogeneic CD19 CAR‑T Included in CDE’s “Care Program‑Extension” – Rare Disease Fast Track for Relapsed/Refractory Systemic Sclerosis

Company Drug

Walvax’s Third‑Generation COVID‑19 mRNA Vaccine Wins NMPA Approval – JN.1‑Based Shot Clears Regulatory Bar for Adults in China

Policy / Regulatory

China’s Seventh National VBP Round for Medical Consumables Concludes in Tianjin – 517 Digestive Intervention Products Selected Across 23 Categories

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.